{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Figure 2:', 'Study Design Schematic', 'Study Population: Patients', 'Duration of Treatment:', 'with recurrent or metastatic', 'Treatment until PD,', 'cervical cancer that has', 'unacceptable toxicity, or', 'progressed after platinum', 'until 96 weeks (16cycles,', 'therapy for recurrent or', 'each 6 weeks)', 'metastatic cervical cancer', 'Option for treatment', 'Experimental Therapy', 'Cemiplimab', 'beyond progression', '350 mg IV Q3W', 'with cemiplimab', 'Option for', 'retreatment for', 'patients who', 'Screening, Randomization,', 'complete 16 cycles', 'and Stratification (N = 590):', 'and then experience', 'Randomization - 1:1', 'PD in post-treatment', 'Stratification:', 'follow up', 'Histology- Squamous', 'Control Therapy,', 'Post-Treatment', 'versus adenocarcinoma/', \"Investigator's Choice\", 'adenosquamous', 'Follow-up:', 'Any of the following, given IV Q3W:', 'Geographic region', 'Anti-folate:', 'For safety, progression', 'Prior bevacizumab (Y/N)', 'Pemetrexed 500 mg/m\u00b2 on', 'events, and os', 'ECOG PS 0 VS 1', 'Day 1(Q3W)', 'Study Endpoints:', 'Topoisomerase inhibitor', 'Topotecan 1.0 mg/m\u00b2 on Days 1-5', 'Primary: os', '(Q3W)', 'OR', 'Key Secondary: PFS,', 'Irinotecan 100 mg/m\u00b2 weekly x4', 'ORR', \"followed by 10-14 days' rest\", '(Q42D)', 'Nucleoside analog:', 'Gemcitabine 1000 mg/m\u00b2 on', 'Days 1 and 8 (Q3W)', 'Vinca alkaloid:', 'Vinorelbine 30 mg/m2 on', 'days 1 and 8 (Q3W)', 'Q42D=every 42 days', 'Regeneron Pharmaceuticals, Inc.', 'Page 45 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'The study includes 3 periods: screening, treatment, and follow-up. The screening period begins', 'with the signing of the informed consent form (ICF). The screening period ends when the patient', 'has been confirmed as fully eligible for the study and is randomized, or with confirmation that the', 'patient is ineligible and is a screen failure. The treatment period begins within 5 days of', 'randomization to 1 of the treatment arms. Cycle length is 6 weeks, and tumor imaging is planned', 'to be conducted on day 42 (7 days) of cycles 1-4, 6, 8, 10, 12, 14, and 16. Planned treatment is', 'for up to 96 weeks. The treatment phase ends when the patient discontinues study therapy. There', 'is no cross-over during this study. After completion of the treatment period, patients enter the', 'follow-up period. After the follow-up period, patients will be followed for survival.', 'Study closeout procedures will be implemented after last patient last visit of the cemiplimab', 'Extension Phase (Section 7.1.7.1).', '5.1.1.', 'End of Treatment Definition', 'There is an end of treatment disposition point for each patient, as reflected by treatment', 'completion/discontinuation case report form (CRF). The end of treatment occurs for each', 'individual patient after the patient completes or discontinues from the treatment (Table 1), but', 'before follow-up visits 1 and 2 (Table 2).', '5.1.2.', 'End of Study Definition', 'The end of study for the study as a whole is planned to occur when approximately 340 deaths have', 'occurred in squamous cell patients, as per Section 10.2. The total duration of study from start of', 'randomization to final analysis of OS is expected to be approximately 42 months (33 months of', 'accrual plus 11 months of follow-up). There is an end of study disposition point for each patient,', 'as reflected by study completion/discontinuation CRF. The end of study occurs for each individual', 'patient after the patient completes or discontinues from the treatment (Table 1) and/or follow-up', 'visit 1 and 2 portion of Table 2, but before the survival follow-up portion of Table 2.', 'Due to survival benefit, for patients on the cemiplimab arm on second interim analysis, a', 'cemiplimab Extension Phase was added (Section Section 7.1.7). Therefore, end of study is now', 'planned to occur after last patient last visit of the cemiplimab Extension Phase.', '5.2.', 'Planned Interim Analysis', \"Two interim efficacy analyses are planned using Lan-DeMets (O'Brien-Fleming) spending\", 'function. The first interim efficacy analysis will be performed after observing approximately', '238 os events (70% of total os events). The second interim efficacy analysis will be performed', 'after observing approximately 289 os events (85% of total OS events). The details are provided', 'in Section 10.5.', '5.3.', 'Study Committees', '5.3.1.', 'Independent Data Monitoring Committee', 'An Independent Data Monitoring Committee (IDMC) composed of members who are independent', 'from the sponsor and the study investigators will monitor patient safety by conducting formal', 'reviews of accumulated safety data and available efficacy data. The IDMC will also monitor and', 'Regeneron Pharmaceuticals, Inc.', 'Page 46 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}